MedTrace Logo

Study on the Efficacy and Timing of ECMO Therapy in Children With Refractory Septic Shock

NCT03948048 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-03-16

No results posted yet for this study

Summary

Severe sepsis and septic shock remain the leading causes of child mortality worldwide. Sepsis is a complex process that ultimately leads to circulation disorders, organ perfusion abnormalities, capillary leakage, tissue hypoxia, and organ failure. The difficulty of clinical treatment is microcirculation and mitochondrial dysfunction in septic shock. Once shock enters the stage of microcirculation failure, conventional treatment is ineffective. ECMO can effectively support the circulatory system and provide good oxygen delivery, but there are many controversies in clinical treatment. 1) whether ECMO can effectively improve the clinical prognosis of children with septic shock; 2) appropriate timing for ECMO intervention; 3) which key clinical factors affect the effect of ECMO treatment. This study intends to adopt a multi-center, prospective, non-randomized controlled trial design, and the main research hypothesis is whether ECMO treatment can improve the success of discharge survival of children with septic shock.

Conditions

  • Septic Shock
  • Extracorporeal Membrane Oxygenation Complication

Interventions

DEVICE

ECMO

ECMO is used to intervene septic shock and refractory septic shock

Sponsors & Collaborators

  • Shanghai Children's Hospital

    collaborator OTHER

  • Beijing Children's Hospital

    collaborator OTHER

  • Zhengzhou Children's Hospital, China

    collaborator OTHER

  • Chinese PLA General Hospital

    collaborator OTHER

  • The Children's Hospital of Zhejiang University School of Medicine

    collaborator OTHER

  • Children's Hospital of Chongqing Medical University

    collaborator OTHER

  • Shengjing Hospital

    collaborator OTHER

  • Children's Hospital of Fudan University

    lead OTHER

Principal Investigators

  • Guoping Lu, Doctor · Children's Hospital of Fudan University

Eligibility

Min Age
29 Days
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03948048 on ClinicalTrials.gov